BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37822222)

  • 1. A randomized, double-blind, placebo-controlled trial with mannan-conjugated birch pollen allergoids.
    Mösges R; Zeyen C; Raskopf E; Acikel C; Sahin H; Allekotte S; Cuevas M; Shamji MH; Subiza JL; Casanovas M
    Allergy; 2024 Apr; 79(4):990-1000. PubMed ID: 37822222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study.
    Spertini F; DellaCorte G; Kettner A; de Blay F; Jacobsen L; Jutel M; Worm M; Charlon V; Reymond C
    J Allergy Clin Immunol; 2016 Jul; 138(1):162-8. PubMed ID: 27373329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-response relationship of a new Timothy grass pollen allergoid in comparison with a 6-grass pollen allergoid.
    Pfaar O; Hohlfeld JM; Al-Kadah B; Hauswald B; Homey B; Hunzelmann N; Schliemann S; Velling P; Worm M; Klimek L
    Clin Exp Allergy; 2017 Nov; 47(11):1445-1455. PubMed ID: 28696503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy with a modified birch pollen extract in allergic rhinoconjunctivitis: clinical and immunological effects.
    Ceuppens JL; Bullens D; Kleinjans H; van der Werf J;
    Clin Exp Allergy; 2009 Dec; 39(12):1903-9. PubMed ID: 20085600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma.
    Pfaar O; Bachert C; Kuna P; Panzner P; Džupinová M; Klimek L; van Nimwegen MJ; Boot JD; Yu D; Opstelten DJE; de Kam PJ
    J Allergy Clin Immunol; 2019 Mar; 143(3):970-977. PubMed ID: 30508538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.
    Pauli G; Larsen TH; Rak S; Horak F; Pastorello E; Valenta R; Purohit A; Arvidsson M; Kavina A; Schroeder JW; Mothes N; Spitzauer S; Montagut A; Galvain S; Melac M; André C; Poulsen LK; Malling HJ
    J Allergy Clin Immunol; 2008 Nov; 122(5):951-60. PubMed ID: 19000581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy With the SQ Tree SLIT-tablet in Adults and Adolescents With Allergic Rhinoconjunctivitis.
    Mäkelä MJ; Gyllfors P; Valovirta E; Steffensen MA; Grønager PM; Savolainen J; Winther L
    Clin Ther; 2018 Apr; 40(4):574-586.e4. PubMed ID: 29551533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms.
    Kruse K; Gerwin E; Eichel A; Shah-Hosseini K; Mösges R
    J Allergy Clin Immunol Pract; 2015; 3(3):381-6. PubMed ID: 25609338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of birch pollen allergoid subcutaneous immunotherapy: A 2-year double-blind, placebo-controlled, randomized trial plus 1-year open-label extension.
    Worm M; Rak S; Samoliński B; Antila J; Höiby AS; Kruse B; Lipiec A; Rudert M; Valovirta E
    Clin Exp Allergy; 2019 Apr; 49(4):516-525. PubMed ID: 30570787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis: results of a phase II study.
    Pfaar O; van Twuijver E; Boot JD; Opstelten DJ; Klimek L; van Ree R; Diamant Z; Kuna P; Panzner P
    Allergy; 2016 Jan; 71(1):99-107. PubMed ID: 26417901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study.
    Bødtger U; Poulsen LK; Jacobi HH; Malling HJ
    Allergy; 2002 Apr; 57(4):297-305. PubMed ID: 11906359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Effect of the Tree Pollen SLIT-Tablet on Allergic Rhinoconjunctivitis During Oak Pollen Season.
    Nolte H; Waserman S; Ellis AK; Biedermann T; Würtzen PA
    J Allergy Clin Immunol Pract; 2021 May; 9(5):1871-1878. PubMed ID: 33548518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intradermal Phleum pratense allergoid immunotherapy. Double-blind, randomized, placebo-controlled trial.
    Sola Martínez FJ; Barranco Jiménez RM; Martín García C; Senent Sánchez C; Blanco Guerra C; Fernández-Rivas M; Vega Castro A; Dávila González I; Carbonell Martínez A; Panizo Bravo C; Gómez Torrijos E; Rodríguez Gil D; Palacios Peláez R
    Clin Exp Allergy; 2020 Dec; 50(12):1352-1361. PubMed ID: 32946612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intralymphatic immunotherapy with birch and grass pollen extracts. A randomized double-blind placebo-controlled clinical trial.
    Ahlbeck L; Ahlberg E; Stuivers L; Björkander J; Nyström U; Retsas P; Govindaraj D; Jenmalm MC; Duchén K
    Clin Exp Allergy; 2023 Aug; 53(8):809-820. PubMed ID: 37013723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy.
    Worm M; Higenbottam T; Pfaar O; Mösges R; Aberer W; Gunawardena K; Wessiepe D; Lee D; Kramer MF; Skinner M; Lees B; Zielen S
    Allergy; 2018 Sep; 73(9):1812-1822. PubMed ID: 29779247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen-induced allergic rhinoconjunctivitis in an environmental exposure unit.
    Ellis AK; Tenn MW; Steacy LM; Adams DE; Day AG; Walker TJ; Nolte H
    Ann Allergy Asthma Immunol; 2018 May; 120(5):495-503.e2. PubMed ID: 29432967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis.
    Kopp MV; Brauburger J; Riedinger F; Beischer D; Ihorst G; Kamin W; Zielen S; Bez ; Friedrichs F; Von Berg A; Gerhold K; Hamelmann E; Hultsch ; Kuehr J
    J Allergy Clin Immunol; 2002 Nov; 110(5):728-35. PubMed ID: 12417881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerated Up-Dosing of Subcutaneous Immunotherapy with a Registered Allergoid Birch Pollen Preparation.
    Buczyłko K; van der Werf JF; Boot D; van Ree R
    Int Arch Allergy Immunol; 2017; 172(3):183-186. PubMed ID: 28380494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-in-human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy.
    Nieto A; Mazón Á; Nieto M; Ibáñez E; Jang DT; Calaforra S; Alba P; Pérez-Francés C; Llusar R; Montoro J; de Mateo A; Alamar R; El-Qutob D; Fernández J; Moral L; Toral T; Antón M; Andreu C; Ferrer Á; Flores IM; Cerdá N; Del Pozo S; Caballero R; Subiza JL; Casanovas M
    Allergy; 2022 Oct; 77(10):3096-3107. PubMed ID: 35570712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin G4-antibodies to rBet v 1 and risk of sensitization and atopic disease in the child.
    Kihlström A; Hedlin G; Pershagen G; Troye-Blomberg M; Härfast B; Lilja G
    Clin Exp Allergy; 2005 Dec; 35(12):1542-9. PubMed ID: 16393319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.